logo-loader
viewCytoDyn Inc.

CytoDyn sees positive results as first triple-negative breast cancer patient treated with leronlimab

The company said early data from the first patient enrolled show no detectable circulating tumor cells in the peripheral blood

CytoDyn - CytoDyn Inc announces additional early Phase 1b/2 clinical trial results of its lead drug leronlimab in patients with CCR5 metastatic triple-negative breast cancer
A second patient with metastatic breast cancer has been enrolled in the trial under an emergency use IND process

CytoDyn Inc (OTCMKTS:CYDY) announced Tuesday additional early Phase 1b/2 clinical trial results of its lead drug leronlimab in patients with CCR5 metastatic triple-negative breast cancer. 

In a statement, the company said data from the first patient enrolled show no detectable circulating tumor cells (CTC) in the peripheral blood and additional reductions in CCR5 expression on cancer-associated cells at eight weeks. 

A second patient with metastatic breast cancer has been enrolled in the trial under an emergency use investigational new drug (IND) process, CytoDyn said. 

READ: CytoDyn has multiple shots on goal with its flagship drug leronlimab as cure for HIV, various cancers

The first patient in the open-label study was given a weekly injection of leronlimab at 700mg along with carboplatin. The patient was enrolled in the trial with CCR5-positive, triple-negative breast cancer and naïve to chemotherapy in a metastatic setting. The patient was previously exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings.

“It is very exciting to see additional preliminary results that demonstrate leronlimab’s potential as a therapeutic option to treat mTNBC,” said CEO Nader Pourhassan.

He said that if the results of the second patient under an emergency IND are similarly impressive as the first patient, CytoDyn plans to file for Breakthrough Therapy designation before the end of January 2020. 

“We have had many patients contact us for treatment under our expanded access protocol and another hospital has opened enrollment for our mTNBC trial,” he added. “We look forward to continuing our research in furtherance of this clinical development plan.”

CytoDyn, based in Vancouver, Washington, is developing leronlimab to battle multiple diseases. The company has filed an IND application and a Phase 2 clinical trial protocol with the US Food and Drug Administration for leronlimab to treat patients with non-alcoholic steatohepatitis (NASH). 

Leronlimab has also already completed nine clinical trials and been given to 800 patients in HIV treatment programs, without a single drug-related serious adverse event. CytoDyn is also exploring leronlimab's use in the treatment of inflammatory conditions and autoimmune diseases.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: CytoDyn Inc.

Price: 0.294 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $114.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals positive data on metastatic triple-negative...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive it has released additional early Phase 1b/2 clinical trial results of its lead drug leronlimab in patients with CCR5 metastatic triple-negative breast cancer. Pourhassan says representatives from its lab called him crying, revealing...

5 days, 8 hours ago

2 min read